Abstract
Among Italy, Spain, and Japan, the age distributions of novel coronavirus (COVID-19) mortality show only small variation even though the number of deaths per country shows large variation. To understand the determinant for this situation, we constructed a mathematical model describing the transmission dynamics and natural history of COVID-19 and analyzed the dataset of fatal cases of COVID-19 in Italy, Spain, and Japan. We estimated the parameter which describes the age-dependency of susceptibility by fitting the model to reported data, taking into account the effect of change in contact patterns during the outbreak of COVID-19, and the fraction of symptomatic COVID-19 infections. Our modelling study revealed that if the mortality rate or the fraction of symptomatic infections among all COVID-19 cases does not depend on age, then unrealistically different age-dependencies of susceptibilities against COVID-19 infections between Italy, Japan, and Spain are required to explain the similar age distribution of mortality but different basic reproduction numbers (R0). Variation of susceptibility by age itself cannot explain the robust age distribution in mortality by COVID-19 in those three countries, however it does suggest that the age-dependencies of i) the mortality rate and ii) the fraction of symptomatic infections among all COVID-19 cases determine the age distribution of mortality by COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
R.O. acknowledges support from the Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Young Scientists 19K20393. Y.N. was supported by JSPS Grant-in-Aid for Young Scientists (B) 16K20976.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All relevant data are within the manuscript and Supporting Information files.